NCT02791750已完成不适用
5 Years Follow-up in the Lorraine Institute of Oncology With Adjuvant Therapy for Women With Breast Invasive Carcinoma
Institut de Cancérologie de Lorraine1 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2016年6月3日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 150
- 试验地点
- 1
- 主要终点
- Factors associated with persistence to hormone therapy for breast cancer
研究概览
简要总结
Non-persistence to adjuvant hormonal therapy for breast cancer at 5 years decrease its efficacy. The objective of this study is to know the women experience (persistence, treatment changes, quality of life) and its determinants, in a french population.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Patients following-up in the Lorraine Institute of Oncology at 5 years of the beginning of an adjuvant hormonal therapy
- •Women with breast invasive carcinoma positive-RH and indication of adjuvant hormonal therapy
- •Adult patients
- •Being capable and agree to follow the study procedure
- •Patients informed and non-opposed
- •Covered by social security
排除标准
- •History of other cancer except basal cell carcinoma
- •Patients with breast invasive carcinoma negative-RH
- •Synchronous metastases
- •Previous adjuvant hormonal therapy
- •Patients with guardianship
结局指标
主要结局
Factors associated with persistence to hormone therapy for breast cancer
时间窗: 1 day
Women will be classed as persistent if they don't discontinue or abandon hormone therapy during the 5 years after the introduction of the medication. The information will be recorded thanks to a self-questionnary fulfilled the inclusion day. The baseline characteristics will be compared between persistent women and non-persistent women.
次要结局
- Proportion of women with a change in their treatment(1 day)
- Comparison of the quality of life(1 day)
- Cause of treatment discontinuation(1 day)
- Continued homonotherapy(1 day)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Deescalation of Endocrine Therapy Duration in Women With HR+ HER2- Breast Cancer at Very Low RiskBreast CancerNCT05297617UNICANCER696
已完成
不适用
Observational Study to Evaluate Mechanisms of Aromatase Inhibitor Associated Musculoskeletal SymptomsArthralgiaBreast CancerNCT02118636Lynn Henry75
已完成
3 期
HABITSHormonal replacement therapy after breast cancer diagnosis - is it safe?Breast CancerACTRN12607000038493Regional Oncologic Centre, Sweden1,300
已完成
不适用
Impact of Adjuvant Hormone Therapy on Bone and Cardiovascular RiskBreast CancerNCT05049031University Hospital, Toulouse102
进行中（未招募）
不适用
Hormonothérapie adjuvante du cancer du sein : Pharmacocinétique du tamoxifène et des anti-aromatases, corrélation avec les caractéristiques pharmacogénétiquesProtocole PHACS (Pharmacologie de l’Hormonothérapie Adjuvante dans le Cancer du Sein) - PHACSCancer du sein en situation adjuvanteMedDRA version: 12.1Level: PTClassification code 10006187Term: Breast cancerEUCTR2009-018090-30-FRInstitut Claudius Regaud